Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Tafinlar + MekinistⓇ - BRAF inhibitor and MEK inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04940052 (CDRB436J12301) Thyroid cancer Phase 3 150 Progression Free Survival Arm 1: Experimental: Dabrafenib plus trametinib Participants will be treated with dabrafenib twice daily and trametinib once daily Arm 2: Placebo Comparator: Placebo dabrafenib plus placebo trametinib Participants will receive placebo dabrafenib twice daily and placebo trametinib once daily Previously treated patients with locally advanced or metastatic, radio-active lodine refractory BRAFV600E mutation-positive differentiated thyroid cancer Target Patients Read-out Milesstone(s) 2024 Publication TBD 115 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation